Form 4: Corcept Therapeutics Officer Lyon Exercises Options and Sells Shares
SEC Form 4 Filing
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on July 1, 2024, according to a recent SEC filing.
Summary
- On July 1, 2024, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options to acquire 5,000 shares of common stock at a price of $11.35 per share.
- Simultaneously, Lyon sold 5,000 shares of common stock at a weighted average price of $32.4904 per share, with individual sale prices ranging from $32.49 to $32.70.
- Following these transactions, Lyon directly owns 9,290 shares of Corcept Therapeutics common stock.
- This includes 2,560 shares underlying unvested restricted stock awards granted on September 1, 2023, December 1, 2023, March 1, 2024, and June 1, 2024, which vest on the one-year anniversary of the grant date.
- Lyon also holds options to purchase 9,167 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment. The filing simply reports transactions. The sale was under a 10b5-1 plan, reducing the significance of the sale as a sentiment indicator.
Positives
- The exercise of stock options indicates a belief in the company's future prospects, at least at the time the options were granted.
Negatives
- The sale of shares by an officer could be interpreted negatively by some investors, although it was conducted under a pre-arranged 10b5-1 trading plan.
Risks
- Executive stock sales can sometimes signal a lack of confidence in the company's short-term prospects, although this sale was part of a pre-planned trading strategy.
Industry Context
Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, transactions under 10b5-1 plans are often pre-scheduled and may not reflect current sentiment.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/01/2023 | Date of restricted stock award grant to the Reporting Person by the Issuer. |
| 12/01/2023 | Date of restricted stock award grant to the Reporting Person by the Issuer. |
| 03/01/2024 | Date of restricted stock award grant to the Reporting Person by the Issuer. |
| 06/01/2024 | Date of restricted stock award grant to the Reporting Person by the Issuer. |
| 07/01/2024 | Date of stock option exercise and share sale. |
| 02/08/2029 | Expiration date of stock options. |
| 07/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.